Immune cell therapy shows promise for advanced melanoma in early trial
NCT ID NCT05869539
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This early-phase trial tests a new combination treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) grown in the lab and given back along with a drug called ANV419 to help them multiply. The main goal is to check safety and side effects, and researchers will also measure how well the tumors shrink. Only 10 participants are enrolled, so results are preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Basel
Basel, Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.